Pharma companies directory 2026

Pharmaceutical Companies in Algeria

Algeria built one of Africa’s largest formulation industries by telling importers they would lose the right to land a finished pack once a local plant could make the same molecule, then routing hospital volume through a single buyer.

The Ministry of Pharmaceutical Industry now tells the press that domestic factories cover around four fifths of national needs and that more than two hundred establishments hold licences, with Saidal, Biopharm, Merinal, Frater-Razes, LDM and Hikma’s El Kendi site among the plants that feed both community pharmacies and the Pharmacie Centrale des Hôpitaux. ANPP in Staouéli registers every product and inspects sites; the dinar price list and a preference for locally made SKUs decide whether a foreign dossier is worth filing. Sanofi, Pfizer, Novartis and Roche still operate Algerian affiliates, often with toll or joint-venture production rather than pure import. Anyone planning a launch has to treat PCH award cycles and ANPP timelines as the commercial calendar, not as background regulation.

Updated September 2026 · ANPP — Agence Nationale des Produits Pharmaceutiques, registration and licensed establishments as of September 2026 · 18 named accounts

Request a proposal for Algeria Browse the 18 companies

~80%

Share of national medicine needs the ministry says is met by local plants, 2024–2025 statements

200+

Licensed pharmaceutical establishments cited by the Ministry of Pharmaceutical Industry

$515m

Medicine import bill in 2024, down from about $1.25bn in 2022, per the same ministry

PCH

Single public hospital buyer for most institutional packs

Named accounts

Top pharmaceutical companies in Algeria

Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against ANPP — Agence Nationale des Produits Pharmaceutiques, registration and licensed establishments (as of 2026-09-04).

#	Company	HQ	Type	Therapeutic focus	Notes
01	Saidal	Algiers	Local	Essential generics, oncology transfers, insulin and hospital lines	State-owned group and the political face of import substitution; PCH buyers still treat a Saidal award as the default for many essential and newly localised specialty SKUs.
02	Biopharm	Algiers	Local	Branded generics, oncology solids and licensed multinational brands	Largest private Algerian manufacturer, with a history of AstraZeneca and other licence deals and a recent push into anti-cancer tablets that used to be imported.
03	LDM Santé	Algiers	Local	Generics, diagnostics-adjacent products and pharmacy brands	Algerian house that sits in both the medicine and diagnostics conversation, useful when a study needs a mid-sized local comparator rather than Saidal or Biopharm.
04	Merinal	Algiers	Local	Primary-care generics and chronic-care solids	Private laboratory that shows up in community-pharmacy audits across Algiers and the Mitidja as a consistent branded-generic alternative to multinational SKUs.
05	Frater-Razes	Algiers	Local	Generics named for the medieval physician al-Razi; broad primary-care range	Domestic manufacturer whose packs are widely recognised in the independent trade and that benefits from the same import-substitution shield as its larger peers.
06	HUPP	Algiers	Local	Formulation for the Algerian pharmacy and hospital channels	Local industrial name that appears on ANPP establishment lists and in PCH bidder files; treat it as part of the mid-tier manufacturing bench, not as a multinational affiliate.
07	Hikma Algeria (El Kendi)	Algiers	Regional	Branded generics and injectables from the former El Kendi plants	Hikma bought El Kendi and thereby inherited one of the more capable private sites in the country, so Jordanian management now sits inside the local-production system rather than outside it.
08	Sanofi Algeria	Algiers	MNC	Diabetes, consumer health, established brands and local fill-finish	Longest-standing large innovator industrial presence; public statements in recent years have put a majority of its Algerian volume on local lines rather than on import.
09	Pfizer Algeria	Algiers	MNC	Vaccines, anti-infectives, specialty and hospital brands	Affiliate that pairs a commercial team with localisation arrangements so that PCH and ANPP do not treat the portfolio as a pure import book.
10	Novartis Algeria	Algiers	MNC	Cardiology, ophthalmology, oncology and immunology	Specialty-heavy affiliate whose hospital brands still need PCH listing even when the community-pharmacy story is secondary.
11	Roche Algeria	Algiers	MNC	Oncology, haematology and diagnostics	Innovator office that lives or dies on CHU formulary access and on whatever localisation ANPP and the ministry demand for high-value biologics.
12	BeKer Laboratoires	Algiers	Local	Generics and licensed products for the pharmacy channel	Private Algerian laboratory that competes in the same substitution space as Merinal and Frater-Razes and is a frequent mid-tier name in retail audits.
13	Biotic	Algiers	Local	Domestic generics and hospital-adjacent lines	Another locally owned plant group that benefits from import bans on molecules it already makes, so its commercial fate is tied to ANPP’s localisation calls.
14	SOPHAL	Algiers	Local	Algerian formulation for essential and branded generics	Société Pharmaceutique Algérienne, a domestic manufacturer that appears in industry inventories of active plants feeding the pharmacy channel.
15	Pharmacie Centrale des Hôpitaux (PCH)	Algiers	Government	Central purchasing, warehousing and delivery for public hospitals	If a product is meant for CHUs, this is the buyer: awards, strategic stock and distribution sit here, which is why hospital share studies start with PCH circulars rather than with ward-level orders.
16	ANPP (Agence Nationale des Produits Pharmaceutiques)	Staouéli	Government	Registration, GMP inspection and quality control of medicines and devices	The regulator created to take over registration from older structures; E-TASJIL is now the front door, and a negative localisation opinion can kill an import strategy.
17	Institut Pasteur d’Algérie	Algiers	Government	Vaccines, sera and public-health biologics	Public biologics institute that still matters for immunisation supply and for any conversation about local vaccine or serum capacity.
18	CNAS (Caisse Nationale des Assurances Sociales)	Algiers	Government	Social-security reimbursement of outpatient medicines	The outpatient payer that decides whether a community-pharmacy SKU is a reimbursed chronic-care product or a cash item, complementary to PCH’s hospital role.

Primary research

These are the pharmaceutical companies accounts we study in Algeria

Need account-level or SKU-level data for a brand in Algeria? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

Planning research in Algeria?

Primary research, market access & HEOR. Proposals within 48 hours.

Top market research companies in Algeria (2026)

How the market is structured

PCH buying, ANPP files and the local-production obligation

A medicine may be sold only after ANPP issues a registration and, for a plant, a manufacturing authorisation; dossiers now move through the agency’s E-TASJIL portal rather than a paper pile at the old LNCPP. Industrial policy sits on top of that file. When a local site is judged able to supply a molecule, import of the finished equivalent is restricted or refused, which is why so many multinationals signed toll or joint-venture deals instead of defending a pure-import P&L. Public hospitals do not buy molecule by molecule from sales representatives: the Pharmacie Centrale des Hôpitaux aggregates demand, runs the award, holds strategic stock and delivers to CHUs from Algiers to Oran and Constantine. Community pharmacies are a second economy — wholesalers and manufacturer depots feed independents at administered dinar prices — but chronic-care volume still leans on CNAS reimbursement and on whatever PCH has already made familiar inside the hospital. Price control is tight enough that a launch team models the official tariff before it models the field force. The practical sequence for a foreign brand is therefore ANPP advice on whether localisation will be demanded, a plant or toll partner if the answer is yes, a PCH conversation if the product is institutional, and only then a retail detailing plan.

Local

Algerian-owned plants, Saidal among them and a long private bench beside it, that exist because import of a finished equivalent is restricted once ANPP accepts that the molecule can be made at home.

Saidal
Biopharm
LDM Santé
Merinal
Frater-Razes
HUPP
BeKer Laboratoires
Biotic
SOPHAL

Multinational

Innovator affiliates that stayed by putting fill-finish or licence deals on Algerian soil, because a pure-import model now fails both industrial policy and PCH preference.

Sanofi Algeria
Pfizer Algeria
Novartis Algeria
Roche Algeria

Regional

Hikma’s El Kendi inheritance is the clearest Levant-into-Algeria industrial story; other Maghreb or Mashreq groups usually enter as licence partners rather than as greenfield owners.

Hikma Algeria (El Kendi)

Distributors & importers

PCH as the hospital purse, CNAS as the outpatient purse, and ANPP as the gate that decides whether a file is a local product or a doomed import.

Pharmacie Centrale des Hôpitaux (PCH)
ANPP (Agence Nationale des Produits Pharmaceutiques)
Institut Pasteur d’Algérie
CNAS (Caisse Nationale des Assurances Sociales)

What is moving

What is moving the pharmaceutical market in Algeria

Import bans once a local equivalent exists

The industrial rule that closes the border to a finished pack after a domestic site is approved is still the main reason multinationals sign toll contracts and the main reason private Algerian plants can fill capacity.

PCH as a single hospital purse

Winning or losing a PCH lot moves more institutional volume than any detailing cycle, so oncology, insulin and injectable launches are planned around award calendars and delivery performance, not around representative headcount.

Official localisation of insulin and oncology

Ministry statements in 2024–2025 highlighted new insulin units and a first wave of locally made anti-cancer products, including Saidal transfers, which is shifting high-value hospital demand away from import-only originators.

Administered dinar prices

A launch that looks attractive in euros can be unviable once the official tariff is set, so pricing work has to happen before ANPP filing, not after the field force is hired.

BioNixus fieldwork

How BioNixus studies pharmaceutical companies in Algeria

The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Algeria:

Mustapha and Beni Messous (Algiers) plus CHU Oran pharmacy-desk interviews on which local versus imported SKUs actually arrive after a PCH award, and how often wards buy around the system.
Reconstruction of PCH lots for insulin, oncology and large-volume parenterals over recent cycles, tagging bidder nationality and whether a localisation circular had already closed the import route.
Community-pharmacy substitution checks in Algiers and Oran that record administered prices, CNAS codes and the first generic a pharmacist offers when an originator is unnamed.
Confidential conversations with quality heads at private plants about spare capacity for toll manufacture, used when a multinational asks whether an Algerian partner can absorb a newly banned import.

Questions

Frequently Asked Questions

Which manufacturers matter most inside Algeria?

Saidal is the public industrial flagship. Biopharm is the private heavyweight. Merinal, Frater-Razes, LDM, BeKer, Biotic, SOPHAL and Hikma’s El Kendi site fill out the local bench, while Sanofi is the innovator that went furthest into Algerian production.

Does Algeria still import finished medicines?

Yes, especially where no local plant exists — complex biologics, some oncology and orphan products. The ministry’s own figures show the import bill falling sharply from 2022 to 2024 as localisation widened, which is the policy working as designed.

Who buys medicines for Algerian public hospitals?

Pharmacie Centrale des Hôpitaux. Ward pharmacists do not run their own national tenders; they receive what PCH has awarded and delivered. Private clinics are a smaller, separate negotiation.

What does ANPP actually decide?

Registration, plant licensing and quality release. A scientific opinion that a molecule can be made locally is, in practice, also a commercial opinion: import of the finished equivalent becomes much harder after that call.

How does BioNixus work an Algerian pharmaceutical brief?

PCH award reconstruction by molecule; ANPP and ministry circulars on localisation; interviews with CHU pharmacists in Algiers and Oran; and community-pharmacy purchase checks that show how administered prices and CNAS codes shape substitution.

Is the Algerian company table a league ordered by dinar sales?

Read the table as a cast of industrial and institutional actors, not as a league ordered by dinar sales. Inclusion follows recurrence in ANPP and PCH work, not a published share ranking.

Sources

Data sources & methodology

This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Algeria. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

Primary register: ANPP — Agence Nationale des Produits Pharmaceutiques, registration and licensed establishments, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Algeria, not size.

Ministry of Pharmaceutical Industry statements on local coverage, establishment counts and the 2022–2024 import-bill decline, carried by APS / El Watan / EcoTimes
ANPP institutional site and E-TASJIL guidance on registration roles, Staouéli, consulted 2026
PharmaBoardroom and Oxford Business Group background on PCH, Saidal and the 70-percent industrial target
BioNixus Algeria hospital, PCH and pharmacy fieldwork, 2023–2026

BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

48-hour proposal

Need brand and competitor data in Algeria?

Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

Planning research in Algeria?

Primary research, market access & HEOR. Proposals within 48 hours.

Pharmaceutical Companies in Algeria

Top pharmaceutical companies in Algeria

These are the pharmaceutical companies accounts we study in Algeria

Planning research in Algeria?

PCH buying, ANPP files and the local-production obligation

Local

Multinational

Regional

Distributors & importers

What is moving the pharmaceutical market in Algeria

Import bans once a local equivalent exists

PCH as a single hospital purse

Official localisation of insulin and oncology

Administered dinar prices

How BioNixus studies pharmaceutical companies in Algeria

Related research and directories

Frequently Asked Questions

Data sources & methodology

Need brand and competitor data in Algeria?

Planning research in Algeria?